Business
Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway
Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center Company and
About this update from Erasca, Inc.
[{"type":"text","content":"Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center Company and KOL to discuss an overview of unmet medical needs and therapeutic opportunities in cancers driven by the RAS/MAPK pathway, with a particular focus on gastrointestinal cancers SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it will host an investor event on therapeutic opportunities in cancers driven by the RAS/MAPK pathway on Tuesday, April 12 at 4:30 PM Eastern Time. The virtual event will feature presentations from: Key opinion leader Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center, who will comment on therapeutic opportunities and Erasca’s approach to targeting cancers driven by the RAS/MAPK pathway, with a particular focus on gastrointestinal (GI) cancersErasca, who will provide an overview of the company’s pipeline and discuss its clinical development strategy targeting the RAS/MAPK pathway for the treatment of non-small cell lung cancer, GI cancers, hematologic malignancies, and other tumors. Erasca will also highlight the data within its 2022 AACR poster presentations that support its robust clinical development plan A live question and answer session will follow. To register for the event, please click here. A live webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 60 days following the webcast at Erasca.com/events. Scott Kopetz, M.D., Ph.D., received his undergraduate degree from Vanderbilt University, Nashville, TN, in biomedical engineering / electrical engineering. He received his medical degree from Johns Hopkins School of Medicine, Baltimore, MD, and his Ph.D. from the University of Texas Graduate School of Biomedical Sciences, Houston, TX, in patient-oriented biological research / cancer biology. He completed his residency training in internal medicine at Duke University Medical Center, Durham, NC, and was awarded a fellowship in medical oncology at the University of Texas MD Anderson Cancer Center (UTMDACC), Houston, TX. Dr. Kopetz is Deputy Chair of the Departmen...